$TLRY

FALTISCHEK DENISE M purchased $12K of TLRY

FALTISCHEK DENISE M (Chief Strategy Officer) purchased 2,500 shares of Tilray Brands, Inc. (TLRY) at $4.78 on 2026-08-03.

Original reporting
SEC EDGAR · FALTISCHEK DENISE M
Published Aug 4, 2026, 2:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TLRY
Bullish
medium confidence
Mentioned
$TLRY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYBullishLow
01

Why it matters

A new insider open-market purchase was reported, which can slightly influence sentiment but does not change fundamentals on its own.

02

Market read

Traders may note the insider buy, but the disclosed value is small and there is no accompanying corporate catalyst.

03

What to watch

No 10b5-1 plan is cited, but the filing does not explain motivation, timing constraints, or whether the buy is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed today, after-hours/late session visibility

Background

This is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYBullishMedium confidence
Context

Tilray Brands disclosed via Form 4 that Chief Strategy Officer Denise M. Faltischek bought 2,500 shares at $4.7800 on 2026-08-03.

Expected impact

Likely limited near-term impact; may add small incremental bullish sentiment rather than a catalyst.

Evidence & confidence

Form 4 is primary-source and new today, but the transaction value (~$12k) is small relative to typical market-moving thresholds and provides no guidance, deal, or operational change.

Market effects

No clear sector read-through; this is company-specific insider activity without broader regulatory or industry developments.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification rather than a strong fundamental signal, especially at small sizes.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Denise M. Faltischek

    Chief Strategy Officer who purchased 2,500 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.